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Abstract
Alzheimer’s disease (AD) is characterized by neurofibrillary tangles and extracellular amyloid-β
plaques (Aβ). Despite ongoing research, some ambiguity remains surrounding the role of Aβ in
the pathogenesis of this neurodegenerative disease. While several studies have focused on the
mutations associated with AD, our understanding of the epigenetic contributions to the disease
remains less clear. To that end, we determined the changes in DNA methylation in differentiated
human neurons with and without Aβ treatment. We isolated the DNA from neurons treated with
Aβ or vehicle, and digested the two samples with either a methylation-sensitive (HpaII) or a
methylation-insensitive (MspI) restriction endonuclease. The fragments were amplified and cohybridized to a commercial promoter microarray. Data analysis revealed a subset of genomic loci
that shows a significant change in DNA methylation following Aβ treatment in comparison to
the control group. After mapping these loci to nearby genes, we discovered high enrichment for
cell-fate genes that control apoptosis and neuronal differentiation. Finally, we incorporated three
of those genes in a possible model suggesting the means by which Aβ contributes to the brain
shrinkage and memory loss seen in AD.

Keywords: Alzheimer’s disease, DNA methylation, beta amyloid fragment (1-40), neurogenesis
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Introduction
Several lines of evidence suggest that epigenetic modifications, like DNA methylation, play a
role in AD. First, late onset Alzheimer’s disease, which represents over 90% of AD cases,
appears sporadic in nature with no known genetic cause [1]. Consistent with this, the inheritance
pattern of AD in monozygotic twins suggests a non-Mendelian mode of acquiring the disease [24], indicating that DNA sequence alone does not explain AD development. Second, evidence of
a parent-of-origin effect has been described for AD, identifying several genomic regions that are
transmitted through the maternal line to affected individuals [5]. The requirement of an
environmental contribution (in this case being the maternal germ line) is consistent with an
epigenetic mechanism [6]. It is interesting to note that one of the most common mechanisms of
parent-of-origin effects is “genomic imprinting” mediated by DNA methylation [7]. Third,
studies in mice and humans suggest a global change in DNA methylation when comparing AD
subjects to their control counterparts. In humans, monozygotic twins discordant for AD
displayed differential DNA methylation levels in the anterior temporal neocortex, a region
severely affected in AD [8]. The regions of the brain not affected by AD displayed identical
DNA methylation levels, demonstrating the specificity of this result. The specific reduction of
DNA methylation in the AD twin may provide a rationale for the link between folate deficiency
and AD, since one of the normal functions of folate is to donate methyl groups for DNA
methylation reactions [9]. Finally, the expression levels of several AD-associated genes (APP, βAPP cleaving enzyme, and neprylisin) are regulated based on the DNA methylation status of
their respective promoters [10, 11]. It is important to note that although AD is associated with a
global hypomethylation of the genome, the neprylisin (NEP) promoter actually becomes
hypermethylated in murine cerebral endothelial cells treated with Aβ [11]. This evidence
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demonstrates that a gene can be affected by an epigenetic change that increases or decreases its
normal methylated state. NEP expression is significantly reduced in AD brains, most likely due
to methylation-dependent silencing [11, 12]. Taken together, these data strongly suggest that
DNA methylation plays a key role in the development of AD.
The identification of epigenetic marks associated with AD development would provide
excellent diagnostic markers for mapping AD progression and propose a novel, epigenetic model
to how AD initially begins. In addition, a non-mutational, reversible process like DNA
methylation would be vulnerable to the development of epigenetic therapeutics aimed at
preventing or even undoing age-related changes to the genome.
In order to determine if DNA methylation plays a role in AD, human IMR-32 cells were
differentiated into mature neuronal cells and treated with Aβ. The methylation pattern of
individual genomic regions was analyzed using genome-wide promoter arrays. Comparison of
the methylation patterns before and after treatment identified the specific epigenetic changes that
occur as neuronal development progresses toward an AD-like state.
Several methods have been described for detection of the presence of methylated DNA.
Bisulfite sequencing [13] utilizes the chemical differences between methylated and unmethylated
cytosine. Sodium bisulfite reacts with normal cytosine (unmethylated) to form an intermediate
easily deaminated to uracil. Sequencing will reveal a thymine at locations corresponding to
unmethylated cytosines. Conversely, methylated cytosines are protected from the chemical
transition to uracil, so no changes in the base sequence are detected (see [14] for review).
Although reliable, this method is not easily adapted to meet the requirements of a genomic-sized
examination since sequencing at this scale is quite expensive.
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The methylated DNA immunoprecipitation (MeDIP) method [15] uses an antibody to
capture DNA fragments by way of their methylated cytosines. The capture of specific regions is
expressed as a purification enrichment and can be determined using PCR or by hybridizing the
material to genomic chip arrays. The latter platform allows the global determination of
methylated regions. Because this method does not detect unmethylated cytosines, a failure to
detect a CpG region of interest could be due to its hypomethylated state or a technique problem
in the purification process.
Other methods of DNA methylation determination utilize the specificity of restriction
endonucleases for a particular CpG methylation state (methylation-sensitive restriction enzyme;
MSRE) followed by PCR analysis. An example of an MSRE is HhaI, which recognizes and cuts
5’-GCGC-3’ sequences only when they are unmethylated [16]. PCR of the region will produce a
visible product only when the included CpG is methylated and thus protected from enzymatic
digestion. This assay requires additional PCR controls to determine if failed PCR runs are due to
poor primer design or a truly hypomethylated region.
This short coming can be resolved when two MSREs with different methylation
sensitivities are used. For example, HpaII and MspI are isoschizomers that both recognize 5’CCGG-3’ sequences. HpaII digestion is blocked when these sequences are methylated, while
MspI is insensitive to the methylation status of the recognition site. When these fragments are
cohybridized to genomic microarrays (described as HpaII tiny fragment Enrichment by
Ligation-mediated PCR; or HELP assay), intergenomic and intragenomic comparisons
concerning DNA methylation can be made [17]. Because this method can detect methylated and
unmethylated regions on a genomic scale, the HELP assay was the method of choice for this
study.
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Methods and Methods
Cell Culture
Cholinergic IMR-32 human neuroblastoma cells [18] (ATCC) were grown and differentiated as
previously described [19]. The cells were maintained in culture in proliferation medium [MEM
with NEAA (Invitrogen 10370-0210, 2mM L-glutamine, 1mM sodium pyruvate, 10% FCS] at
37°C in an atmosphere of 5% CO2. The cells were plated at a density of 5 × 105 cells/15 cm plate
and grown for 48 hours in this proliferation media. The proliferation media was then replaced by
differentiation media (proliferation medium with 2% FCS and 2mM sodium butyrate). The cells
were maintained in differentiation media for 7 days then treated with either 25 µM Aβ1-40 peptide
(Invitrogen 03-136) (prepared as described previously [11]) or vehicle for 48 hours. The cells
were then rinsed with cold PBS (phosphate-buffered saline), harvested by scraping, pelleted by
centrifugation in 1.5 ml Eppendorf tubes, and stored at -80°C.
DNA Isolation and Digestion
The undifferentiated, differentiated, and Aβ-treated cell pellets were thawed and kept on ice until
they were treated with 478 µl of lysis buffer (0.5% SDS, 0.2M NaCl, 20mM EDTA), 20 µl
protease K (2.5 mg/ml), and 2 µl RNase (10mg/ml). The reagents were mixed with the pellets by
gentle agitation, and the tubes were incubated in a 42°C water bath overnight. Each sample was
treated with 500 µl of phenol-chloroform-isoamyl alcohol (PCIAA) and incubated on a rotary
wheel for 10 minutes at 37°C. The samples were then separated into an organic and aqueous
layer by centrifuging at 17,000×g for 5 minutes. The aqueous layer containing the DNA in each
sample was transferred to a new 1.5 ml Eppendorf tube. This process was repeated once to
ensure DNA purity. To precipitate the DNA, 3× the sample volume in 100% ethanol was added
to each sample, along with 1/10 the sample volume in 3M sodium acetate and .5 µl of glycogen
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(20 mg/ml). The samples were then centrifuged at 17,000×g for 1 hour. The supernatant was
removed, and the pellets were subsequently washed gently with 70% ethanol. The pellets were
finally resuspended in 200 µl of deionized water. The DNA in each sample was then quantified
using UV spectroscopy.
Each sample was digested with HpaII and MspI in separate reactions according to the
manufacturer’s recommendations. Each reaction contained 1 µg of DNA and either 4 µl of HpaII
(10,000 U/ml) or 2 µl of MspI (20,000 U/ml) (New England Biolabs). The reactions were
brought to a final volume of 200 µl with deionized water and incubated overnight at 37°C. The
DNA from each sample was then purified as described above and resuspended in 15.5 µl of 10
mM Tris-HCl (pH 8).
Ligation-mediated PCR
To avoid degradation or re-annealing of the overhangs, the ligation was performed immediately
after the digestion. Two sets of adapters were used: NHpaII12 (5’-CGGCTTCCCTCG-3’),
NHpaII24 (5’-GCAACTGTGCTATCCGAGGGAAGC-3’), JHpaII12 (5’-CGGCTGTTCATG3’), JHpaII24 (5’-CGACGTCGACTATCCATGAACAGC-3’). The 24-mer and 12-mer
oligonucleotides of each set were annealed together in preparation for the ligation. Ligation was
performed on HpaII and MspI-digested undifferentiated DNA, differentiated DNA, and Aβ
DNA. Reactions were carried out in PCR tubes and consisted of 6 µl of 5× T4 ligase buffer
(Invitrogen), 15.5 µl digested DNA, 4 µl of 50 µM pre-annealed JHpaII linkers, 4 µl of 50 µM
pre-annealed NHpaII linkers, and 1 µl of T4 DNA ligase (4 U/µl). The reactions were put in a
thermocycler at 16°C overnight. The reactions were then diluted to 10 ml by 10 mM Tris-HCl
(pH 8).
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The LM-PCR reactions contained 5 µl of HpaII-digested DNA or 2.5 µl of MspI-digested
DNA, .5 µl of 100 µM JHpaII24 primer, .5 µl of 100 µM NHpaII24 primer, 25 µl of 2× SsoFast
EvaGreen qPCR Supermix (Bio-Rad), and were brought to a final volume of 50 µl with
deionized water. The MspI-digested DNA used in the amplification was half the volume of the
HpaII-digested DNA. This is due to the difference in complexity of fragments in the MspIdigested DNA, which will cause these fragments to amplify and saturate the solution in the PCR
faster and undergo “extra” cycles without amplification. This makes the sample susceptible to
unwanted artifacts. The issue was circumvented by using half as much MspI-digested DNA as
HpaII-digested DNA as was previously reported [17]. The LM-PCR scheme began with an initial
extension step at 72°C for 10 minutes, 15-20 cycles of 95°C for 30 seconds and 72°C for 3
minutes, and a final extension step at 72°C for 10 minutes. The reactions were purified using
Qiagen’s QIAquick PCR Purification Kit (50) according to the manufacturer’s instructions, and
DNA was quantified using UV spectroscopy.
DNA microarrays and data analysis
Five 385K DNA Methylation microarrays were purchased from Roche NimbleGen to hybridize
2 undifferentiated DNA samples, 2 differentiated DNA samples, and 1 DNA sample from
differentiated cells treated with Aβ. All samples were amplified by LM-PCR and purified to
produce at least 4 µg of DNA with a concentration of at least 250 ng/µl.
The raw microarray data from Roche NimbleGen was processed using Matlab 2011.
First, correlation graphs were generated to examine the relationship between the 2
undifferentiated DNA microarrays and between the 2 differentiated DNA microarrays. Each
array contained 4,288 random probes designed by Roche NimbleGen for control purposes. The
background fluorescence threshold was taken as 2.5 mean absolute deviations (MAD) above the
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median fluorescence signal of the random probes [20, 21]. For a probe to be considered valid, the
probe intensity from the MspI sample had to be above the threshold in all 5 arrays. An
HpaII/MspI ratio histogram was generated for each condition (undifferentiated, differentiated,
and Aβ-treated). The undifferentiated and differentiated data were an average of 2 microarray
data sets for those conditions. All histograms were mean-centered, and the x-axis was converted
from linear scale to log2.
QPCR
Site-specific qPCR confirmations were used to validate the microarray data and show their
biological significance. DNA from IMR-32 cells was digested with HpaII and MspI in separate
reactions as described above. An “uncut” control was included to serve as a positive control for
maximum amplification possible. The recipe for the uncut digestion reaction was identical to that
of MspI, except that 2 µl of 50% glycerol were added instead of the enzyme. The samples were
subsequently purified as previously described and resuspended in 200 µl of deionized water.
Primers were designed around the closest 5’-CCGG-3’ to a given probe using Primer3
(http://frodo.wi.mit.edu/). The PCR product size range was chosen to be between 80-140 bp, the
primer Tm was 60±2ºC, and the primer size was 20±2 bp. All other criteria were left as the
default settings by the software. The 25 µl qPCR reactions contained .015-.025 µg of template
DNA, 12.5 µl of 2x Supermix, and forward and reverse primers with a final concentration of
.625 µM each. Reactions lacking DNA template were also included as control for primer selfannealing and amplification. Amplification was performed using a BioRad MJ Mini Personal
Thermal Cycler. The touchdown qPCR scheme began with an initial melting step at 95°C for 5
minutes. The first cycle was repeated 19 times and consisted of a melting step at 94°C for 10
seconds, annealing step at 69°C for 30 seconds, and a final extension step at 72°C for 30
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seconds. The annealing step decreased by 0.5°C each cycle. The second cycle followed
immediately and consisted of a melting step at 94°C for 10 seconds, annealing at 59°C for 30
seconds, and an extension step at 72°C for 30 seconds. This second cycle was repeated 24 times
with a constant annealing temperature and was followed by a final extension step at 72°C for 5
minutes. The amplification graphs were generated by BioRad CFX Manager 2.0. The
quantification cycle (Cq) values were obtained for all samples and used for quantitation.
Gene Ontology
Gene symbols were linked to the 222 most changing regions (111 regions becoming
hypomethylated and 111 regions becoming hypermethylated following Aβ treatment) using
GREAT, a region/gene association and annotation software developed by Stanford University
and Bejarano Lab [22]. Human genome 18 build was used for the species assembly, and the
whole genome was used as the reference list. The resulting gene symbols were analyzed by
GeneCodis, a gene annotation website for ontological assignments [23-25]. The gene symbols
from three methylation categories (regions becoming hypomethylated, hypermethylated, and a
random list) were analyzed using the following GeneCodis criteria: level 7 (the most stringent), a
minimum of 3 genes associated with that ontology, and a chi-square value that was lower than
the lowest obtained chi square value from the random list. The enrichment value from which the
chi-square value was calculated by dividing the ratio of genes for a gene ontology in the list to
the total number of genes in the list by the ratio of genes for that gene ontology in the genome to
the total number of genes in the genome.
Number of Genes for G.O. in List
�
�
Number of Genes in List
Total Number of Genes for G.O.
�Total Number of Genes in Genome�
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Results
Global DNA Methylation Levels Remain Largely Unchanged After Aβ Treatment.
In order to determine if DNA methylation plays a role in the development of AD, we set out to
identify the methylation status of neurons before and after Aβ treatment. We utilized a
microarray-based technique, known as the HELP assay, which compares the endonuclease
efficiency of a methylation-sensitive enzyme (HpaII) versus a methylation-insensitive enzyme
(MspI). These enzymes are isoschizomers that cleave the same 5’-CCGG-3’ palindrome. This
recognition sequence contains a CpG dinucleotide that can serve as the target for de novo
methylation by the DNMT3 family of methyltransferases.
Analysis of the HpaII/MspI ratios before and after Aβ treatment revealed a bi-modal
distribution of DNA methylation levels (Figure 1). In general, this distribution pattern
represented groups of ratios that were hypermethylated or hypomethylated relative to the mean
of all the ratios. Approximately 72.8% of the control ratios fell in the lower distribution
(representing the high methylation fraction), while only 27.2% of the control ratios fell in the
higher distribution (representing the low methylation fraction) (Figure 1A). A similar pattern was
observed after Aβ treatment, with hypermethylated and hypomethylated fractions being 71.8%
and 28.2% of the ratios, respectively (Figure 1B). The correlation of the control and Aβ -treated
ratios was 0.978 (Figure 1B inset), demonstrating the global similarity of these samples.
Interestingly, this correlation was slightly higher than the correlation between two independent
control microarray samples (R = 0.9475; Supplemental Figure 1), indicating a higher variability
in the control replicates than in the control to Aβ comparison. Overall, the Aβ treatment had no
significant effects on the global DNA methylation levels in the neuronal cells.

11

Aβ Alters DNA Methylation of Cell-Fate Genes
Site-specific qPCR Confirms the Microarray Data.
We then analyzed specific loci within our microarray data to determine if we could detect
discrete levels of DNA methylation as indicated by the microarray data. For this purpose, we
randomly chose genomic regions from the microarray dataset to examine the specific HpaII
sensitivity by quantitative PCR. We chose regions that contained log2 HpaII/MspI ratios less than
the mean for the hypermethylated distributions in order to detect high methylation levels (refer to
Figure 1 - blue curves). We also chose regions that contained log2 HpaII/MspI ratios greater than
the mean of the hypomethylated distributions to detect lower levels of DNA methylation (Figure
1 - red curves). We then mapped all the 5’-CCGG-3’ sequences within the regions in order to
design PCR primers to amplify across select restriction sites. Some regions only contained one
restriction site (Figure 2A), while others contained many (Figure 2B and C). When we performed
qPCR analysis of these particular 5’-CCGG-3’ sequences, we found that the site-specific results
were aligned with the microarray data (Figure 2E-H). For example, two hypomethylated regions
were chosen, ChrY:14100892 and Chr4:122212661 (Figure 2A and C), because they contained
probes with log2 values greater than the average of the hypomethylation distribution in Figure 1A
and B, respectively. QPCR analysis of a restriction site in these regions demonstrated low levels
of amplification in the HpaII samples (Figure E and G). This indicates that HpaII is efficiently
cutting these CpG-containing sequences; therefore, these sequences must not be heavily
methylated. Since MspI can cut its restriction site regardless of CpG methylation, qPCR
amplification of MspI-treated DNA should always be low and serves as a negative control. Two
hypermethylated regions were also chosen, Chr16:67328870 and Chr15:94698105 (Figure 2B
and D), because they contained probes with log2 values below the average of the
hypermethylation distribution in Figure 1A and B, respectively. QPCR analysis of these regions
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demonstrated much higher levels of amplification in the HpaII samples relative to the MspI
controls (Figure 2F and H). This indicates that HpaII is relatively inefficient at cleaving these
sites; therefore, these sequences must contain significant levels of DNA methylation. Taken
together, our qPCR-based approach can determine sequence-specific DNA methylation levels
that are consistent with the microarray-based data.
Aβ Induces Significant Changes in DNA Methylation at a Subset of Genomic Locations.
Since Aβ treatment did not affect neuronal DNA methylation levels on a global scale, we
decided to focus our qPCR approach on the specific genomic loci that contained a significant
change in their epigenetic ratio in relation to Aβ treatment. To this end, we subtracted the control
microarray data from the Aβ-treated microarray data and plotted the log2 ratios as a histogram
(Figure 3A). Ratios greater than zero indicated probes that were more hypomethylated in the Aβ
condition, while ratios less than zero indicated probes that were more hypermethylated in the Aβ
condition. Although the resulting data further demonstrates the similarity between the two
datasets (85% of the data are within 1 STD), some regions of major change can be seen at the
extremes of the plot (Figure 3B and C). These specific regions were of the greatest interest to us,
since they represented significant epigenetic alterations as a result of Aβ treatment. We decided
to focus our attention on these regions of greatest absolute change defined as the top 0.1% of all
changing ratios (0.05% gaining methylation; 0.05% losing methylation). This translated into 111
probes that gained methylation and 111 probes that lost methylation as neurons were exposed to
Aβ, and corresponded to probe ratios exceeding 3 standard deviations from the average change
of all probes.
We decided to use our qPCR approach to test if, in fact, we could predict the methylation
change at specific 5’-CCGG-3’ sequences based on the microarray data. We randomly chose 12

13

Aβ Alters DNA Methylation of Cell-Fate Genes
genomic regions from each 111 probe list and designed qPCR primers for two 5’-CCGG-3’
sequences in each region (named ‘upstream’ and ‘downstream’ in relation to the highest
changing probe). As expected, microarray regions that gain methylation in the Aβ condition
(Figure 4A and C; negative bars) contain 5’-CCGG-3’ sequences that are more difficult to cleave
with HpaII when analyzed by qPCR (Figure 4B and D). Likewise, microarray regions that lose
methylation in the Aβ condition (Figure 4E and G; positive bars) contain sequences that are more
easily cleaved by HpaII when analyzed by qPCR (Figure 4F and H). Of all the 5’-CCGG-3’ loci
tested, over 97% confirmed the microarray results (44 out of 45; Supplemental Figures 2 and 3).
QPCR results from only 45 5’-CCGG-3’ loci of the 48 examined were kept since qPCR data
from 3 regions contained bad primer pairs as indicated by their melting curves. It is interesting to
note that both CpGs tested in a given region gave a similar result. This indicates that the
methylation changes that occurred within a particular genomic region were not limited to a
particular 5’-CCGG-3’ sequence, but rather were indicative of several other loci in the region as
well. This is consistent with previous work that demonstrates the spreading of epigenetic marks
and explains the similarity in our independent qPCR analyses within a region (i.e., the upstream
and downstream qPCR results).
Gene Ontology of Aβ-induced Epigenetic Changes Implicates Cell-Fate Pathways.
We next wanted to determine if any of the regions that significantly change their DNA
methylation status (i.e., increase methylation or decrease methylation) were associated with a
particular cellular process. For this purpose, the genomic regions were mapped to the nearest
transcription start site (TSS) using GREAT (http://bejerano.stanford.edu/great/public/html).
Once duplicate gene symbols obtained from this software were removed, ontological
assignments were determined using GeneCodis (http://genecodis.cnb.csic.es). Regions that lost
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DNA methylation as a result of Aβ exposure were found near genes associated with
neurogenesis, neuronal differentiation/development, and the negative regulation of apoptosis
(Table 1). Regions that gained DNA methylation as a result of Aβ exposure were also found near
genes associated with neurogenesis and apoptosis. These cellular pathways were specifically
enriched in our Aβ-induced change lists, since a randomly generated gene list of similar size
failed to produce ontological assignments with similar p-values.
While some epigenetic changes were located over 10kb from the nearest TSS (e.g.,
DLX1), other changes were located at the promoter region (e.g., VHL). While DLX1 was
identified because of a distal epigenetic change downstream of its TSS, it is interesting to note
that it also contained a similar change proximal to its TSS, though the degree of change was not
as great (Figure 5). Since our microarrays primarily focused on promoter proximal regions, it is
not surprising that many epigenetic changes were found near genes (Supplemental Table 1). Of
the regions that lost methylation, 45% were located within 5 kb from the nearest TSS, while only
16% of the regions that gained methylation were in this promoter-proximal window
(Supplemental Figure 4). Although this may indicate different mechanisms of epigenetic control,
future genomic studies that do not contain a promoter bias will determine if Aβ-induced
methylation changes have a preference for loci based on their distance from transcription start
sites.
As a whole, these results support the idea that AD pathology is produced, in part, by the
epigenetic changes that occur within neurons as they age or are exposed to Aβ deposits.
Although it is not known if these changes cause AD or are merely a result of AD progression, we
believe these data further define AD as an epigenetic disease with specific cellular processes
affected by altered methylation.
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Discussion
We can make three conclusions from the results presented herein. First, Aβ treatment of
differentiated neurons in vitro does not change the global DNA methylation levels of the
genome. There is an overall consistency in the distribution of methylation levels between the
control sample and Aβ sample microarrays accompanied by a high correlation in probe values
between these conditions. Second, exposure to Aβ leads to significant changes in methylation at
a subset of loci, while others remain largely unchanged. Third, these significantly changing loci
are associated with genes involved in neuronal differentiation, neurogenesis, and apoptosis
control. Therefore, Aβ may contribute epigenetically to AD progression by propagating neuronal
loss of function and death. This is quite significant since epigenetic modifications are reversible
and might provide an avenue for the future treatment of AD. These modifications might also
provide an epigenetic signature, indicative of the early genomic changes associated with AD.
After mapping the microarray regions showing significant changes in methylation to
nearby genes, we found that some regions were 70-300 bp away from the nearest genes, while
others were more than 150,000 bp away. Although some of those regions are fairly distant from
the nearest TSS, it is well-established that gene regulation can proceed distally through enhancer
mechanisms (see [26, 27] for review). With this in mind, it would be interesting to determine if
these distal changes actually define enhancer regions. It is also important to note that GREAT
software maps input loci to the closest “canonical” TSS of a given gene, potentially ignoring
closer TSS sites. In other words, some of the regions in our data may be closer to a nearby gene
than the results seem to suggest.
It is also important to utilize a better model for studying Aβ pathology, as a cancer-based
model such as ours can introduce a background of methylation levels/patterns foreign to normal
cells. For example, the hypomethylation peak seen in genome-wide DNA methylation profiles in
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Figure 1A and B may be a remnant of the cancerous IMR-32 cell line from which our neurons
were differentiated. This relatively large portion of genomic hypomethylation may be the result
of long repetitive sequences becoming hypomethylated with cancer progression [28-30]. Current
pilot studies using a mouse model system demonstrate a uniform distribution of methylation
patterns, adding credibility to this hypothesis. Therefore, we expect future non-cancer based
models to lack such a hypomethylated peak and be even more indicative of what occurs in an
AD brain.
Given the high enrichment in our gene ontology for cell-fate genes, we developed a
coherent model outlining how Aβ possibly contributes to AD pathology by manipulating three
such genes: DLX1, VHL, and PCNT. Previous work by Cobos et. al. shed light on the
involvement of DLX transcription factors on the migration and differentiation of GABAergic
interneurons [31]. Interestingly, they observed disruption in migration patterns and premature
increase in neurite growth in interneurons of DLX1/2 double mutant mice. Their results
demonstrated the importance of DLX1 and DLX2 in repressing neurite growth and maintaining a
compact cell shape necessary for migration maneuvers. VHL, on the other hand, is a known
tumor suppressor that is mutated in some neoplasms (see [32] for review). The third gene of
interest, PCNT, is known for its involvement in the correct spindle assembly and metaphase
progression during mitosis [33, 34], and some mutations in PCNT are associated with
microcephaly [35]. Keeping in mind that Aβ causes significant hypomethylation of DLX1 and
VHL and hypermethylation of PCNT as we saw, it is possible to suggest that Aβ promotes “dedifferentiation” of normal neurons and prevents neuronal precursor cells from dividing and
replacing the damaged cells (Figure 6). Such effects may contribute to the memory loss and
aberrant brain morphology seen in AD. However, we present this model with some reservations;
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although DNA methylation and demethylation have been traditionally associated with
transcriptional repression and activation, respectively, some important exceptions have been
reported [36-39]. Therefore, without mRNA transcription data, this model requires further
support.
Future studies utilizing in vivo models coupled with expression data will further clarify
the effects of Aβ on neurons by monitoring the outcomes of differentially methylated genes.
Hydroxymethylation is another emerging and interesting epigenetic modification that can
possibly contribute to disease progression. Such experiments can focus on genes associated with
differentiation and tumor suppression (such as DLX1 and VHL) and, in addition, evaluate the
candidacy of Aβ-affected regions far apart from TSSs as distal enhancer regions. Combined with
these efforts to confirm and supplement, our study promotes further exploration of AD from an
epigenetic point of view.
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Figure Legends
Figure 1. Global DNA Methylation Distribution in Neurons Remains Largely Unchanged
After Aβ Treatment In Vitro.
The log2 HpaII/MspI ratios for the control and Aβ-treated microarray probes are plotted as
frequency distributions. The data are mean-centered at zero (vertical grey line), with negative
ratios and positive ratios signifying loci more and less methylated than the mean level of
methylation, respectively. The blue and red curves represent the two components of the bimodal
distribution. Each curve shows the probability of the data of each bin belonging to the left peak
or the right peak of these bimodal distributions. (A) The mean HpaII/MspI ratios of the blue and
the red curve are -0.66 and 1.76, respectively. (B) The mean HpaII/MspI ratios of the blue and
the red curve are -0.76 and 1.95, respectively.
Figure 2. Site-specific qPCR Confirms the Microarray Data.
The landscapes of microarray regions selected for confirmations are plotted with purple bars
representing the probe values. Triangles represent the 5’-CCGG-3’ sequences in those regions.
The qPCR results for the chosen CCGGs (red triangles) are generated by setting the 2^(-(Cq)) of
the MspI-digested DNA qPCR curve to “1” and setting the HpaII bar to represent the value of
2^(-(CqHpaII-CqMspI)).
Figure 3. Aβ Induces High Changes in Methylation Levels in a Subset of Loci.
The data from the control microarray were subtracted from the Aβ-treated microarray data, and
the result is plotted as a frequency distribution. The two dashed boxes represent the “upper” and
“lower” 0.05% regions of all changing regions. A close-up frequency distribution of the “lower”
0.05% of the probes with the highest decrease in HpaII/MspI ratio (B) and a close-up frequency
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distribution of the “upper” 0.05% of the probes with the highest increase in HpaII/MspI ratio (C)
are shown.
Figure 4. Aβ-induced Probe Ratio Changes Correspond to CpG Methylation Changes.
The landscapes of microarray regions selected for confirmations are plotted with purple bars
representing the (Aβ - control) value for the probes. Triangles represent the 5’-CCGG-3’
sequences mapped to the region, with red triangles showing the specific CCGG sequences
selected for qPCR analysis. Two separate sequences were chosen per region, one upstream and
one downstream of the greatest changing probe. The “none” and “Aβ” bars in the qPCR graphs
represent the value of 2^(-(CqHpaII-CqMspI)) in the control and Aβ sample DNA, respectively.
Figure 5. Methylation Changes Occur at Promoter Proximal and Distal Regions.
The microarray landscapes for two genes associated with neuronal differentiation (DLX1) and
cell division (VHL) are shown. The landscapes demonstrate that Aβ-induced methylation
changes can occur at regions proximal (VHL) or distal (DLX1) to the TSS (illustrated by a green
arrow). Note that the x-axis has breaks to eliminate genomic gaps that do not contain probe data.
Figure 6. An Epigenetic Model of Aβ Pathology.
DLX1 protein is involved in repressing the dendrite and axon growth of neurons, preventing
differentiation. By decreasing the methylation at DLX1, Aβ can increase the activity of this gene
and promote the de-differentiation of mature neurons. Aβ also decreases the methylation near the
VHL TSS, and increases methylation near the PCNT TSS; this consequently alters the
expression profile of these genes. Given that VHL is a tumor suppressor and PCNT is a director
of mitotic spindle assembly, such methylation changes may eventually prevent neuronal
precursor cells (NPCs) from dividing and replacing the damaged cells. Put together, these
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alterations decrease the number of functional neurons and may eventually result in the loss of
memory and brain mass seen in Alzheimer’s disease.
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Supplemental Figure Legends
Supplemental Figure 1. Correlation of HpaII/MspI Ratios from Control IMR-32 Cells
A scatter-plot of the probe ratios is shown comparing the microarray data from the individual
control (untreated) replicates. The correlation coefficient was calculated using MatLab.
Supplemental Figure 2. QPCR Confirmation of Regions with an Aβ-induced Methylation
Increase
Regions selected for ontological examination were randomly selected and subjected to qPCR
analysis using differential enzyme digestion. The HpaII/MspI ratios were determined with higher
ratios demonstrating a reduction in HpaII cutting efficiency. Higher ratios reflect an increase in
5’-CCGG-3’ methylation and an increase in protection from HpaII digestion. The white and
black bars in the qPCR graph represent the log10 value of 2^(-(CqHpaII-CqMspI)) in the control and
Aβ sample DNA, respectively. Each region (X-axis) was analyzed twice using different primer
sets as indicated by the two sets of bars per region. An asterisk indicates a region of study where
the qPCR primers failed to work.
Supplemental Figure 3. QPCR Confirmation of Regions with an Aβ-induced Methylation
Decrease
Regions selected for ontological examination were randomly selected and subjected to qPCR
analysis using differential enzyme digestion. The HpaII/MspI ratios were determined with lower
ratios demonstrating an increase in HpaII cutting efficiency. Lower ratios reflect an decrease in
5’-CCGG-3’ methylation and a decrease in protection from HpaII digestion. The white and black
bars in the qPCR graph represent the log10 value of 2^(-(CqHpaII-CqMspI)) in the control and Aβ
sample DNA, respectively. Each region (X-axis) was analyzed twice using different primer sets
as indicated by the two sets of bars per region. An asterisk indicates a region of study where the
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qPCR primers failed to work. One region had a 5’-CCGG-3’ sequence that did not show a
methylation decrease (indicated by a †).
Supplemental Figure 4. Relative Gene Locations of Regions with Aβ-induced Methylation
Changes
The genomic regions with the greatest Aβ-induced methylation change were analyzed by
GREAT to determine the distance to the transcription start site of nearby genes. A histogram of
that distribution is shown with each bar representing the number of regions increasing (yellow)
or decreasing (blue) their methylation status upon Aβ treatment.
Supplemental Table 1. Significantly Changing Regions and Their Relative Distance from
Nearby Genes
An excel sheet of the GREAT output file is given showing the association of each genomic
region to a specific gene symbol. The relative distance from the center of each genomic region to
a nearby transcription start site (TSS) is shown in parenthesis. The methylation status change
(loss or gain) is also indicated.
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Figure 1. Global DNA Methylation Levels Remain Largely Unchanged After Aβ
Treatment.
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Figure 2. Site-specific qPCR Confirms the Microarray Data.
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Figure 3. Aβ Induces Significant Changes in DNA Methylation at a Subset of Genomic
Locations.
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Figure 4. Aβ-induced Probe Ratio Changes Correspond to CpG Methylation Changes.
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Table 1. Aβ Alters the DNA Methylation of Cell Fate Genes.

Gene Set

Gene Ontologya

Genesb

p-valuec

Genes Becoming
Hypomethylated
(107 Genes)

Regulation of Neurogenesis;
CNS Neuron Differentiation

DLX1, DLX2

0*

192

SOX9, NKX6-2

1.87x10-43

61

Regulation of Nervous System
Development

MBP, ACCN1

1.02x10-21

38

Negative Regulation of
Apoptotic Process

VHL, HAND2

1.91x10-17

30

PCNT, SKI

1.66x10-16

29

GAS6, LYST,
ADAM8

2.03x10-10

18

DLL1, MAPK8IP3

7.89x10-10

13

>9x10-7

NA

Neurogenesis;
CNS Development

Genes
Becoming
Hypermethylated
(77 Genes)

Brain Development
Regulation of Apoptotic
Process

Enrichment

Neurogenesis

Randomd
(143 Genes)

None

a

Only ontologies that were considered relevant to the study are listed.

b

Genes found in several ontologies are not listed multiple times for clarity purposes.

c

The p-value for each gene set-ontology association was determined by GeneCodis using Chisquare tests.

d

A random list of regions was generated using MATLAB. This list was subjected to the same
analysis as the list containing the changing regions. No gene ontologies were enriched to the
same degree as the lowest ontology enrichment from the specific list.
* The gene ontology p-value was displayed as zero due to limitations in the calculation input.
The value was too low to be successfully determined, which suggests that it is <1.87x10-43 due
to this p-value being successfully calculated.
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Figure 5. Methylation Changes Occur at Promoter-proximal and Distal Regions.
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Figure 6. An Epigenetic Model of Aβ Pathology
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Supplemental Figure 1. Correlation of HpaII/MspI Ratios from Control IMR-32 Cells
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Supplemental Figure 2. QPCR Confirmation of Regions with an Aβ-Induced Methylation
Increase
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Supplemental Figure 3. QPCR Confirmation of Regions with an AB-Induced Methylation
Decrease
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Supplemental Figure 4. Relative Gene Locations of Regions with Aβ-Induced Methylation
Changes.
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Supplemental Table 1. Significantly Changing Regions and Their Relative Distance from
Nearby Genes
Gene
Symbol
ABCC5
ABCG1
ABHD6
ACCN1
ACP6
ANKLE2
ANO10
ARFGAP2
ARID3A
ASPSCR1
ATRIP
AWAT2
C10orf54
C18orf62
C19orf29
C1QTNF8
C8orf30A
CDH13
CEBPG
CENPJ
CMTM1
DACT2
DHX40
DIO3
DLX1
DLX2
E2F4
EBF3
EIF4G1
EPN3
EXOC3L
F11
FAM18B2
FLJ43860
FUBP3
GLS2
GLTP

Changing Region (distance to TSS)
chr3:185217681-185219221 (-30)
chr21:42527874-42528575 (+15889)
chr3:58197548-58199404 (+177)
chr17:29507738-29508738 (-300)
chr1:145608466-145610038 (+6)
chr12:131806082-131806782 (+42092)
chr3:43637980-43639364 (-108)
chr11:46914026-46915276 (+240344)
chr19:934527-935866 (+58160)
chr17:77545256-77546605 (+17216)
chr3:48462421-48463585 (-219)
chrX:69198265-69200010 (-12625)
chr10:73202947-73204143 (-202)
chr18:71128507-71129207 (+139720)
chr19:3648693-3649393 (-71230)
chr16:1082316-1084088 (+3043)
chr8:145407887-145409553 (+32)
chr16:81217278-81219314 (+217)
chr19:38555648-38556850 (-200)
chr13:24394588-24395818 (-118)
chr16:65156996-65158350 (-178)
chr6:168513887-168514588 (-50987)
chr17:54996867-54998139 (-165)
chr14:100419019-100419719 (-678072)
chr2:172667513-172670300 (+10453)
chr2:172667513-172670300 (+6817)
chr16:65782768-65783768 (-301)
chr10:131576120-131576820 (+75611)
chr3:185514249-185515987 (-547)
chr17:45968821-45969521 (+4124)
chr16:65782768-65783768 (-1660)
chr4:187529470-187530572 (+105909)
chr17:15406976-15408370 (-103)
chr8:142839591-142840292 (-253430)
chr9:132443980-132445317 (-132)
chr12:55167668-55169248 (-10)
chr12:108767404-108768105 (+34921)
41

AB-induced
Change
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
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GRIN3B
HAND1
HAND2
HMOX2
HOXB5
IFT140
IGBP1
ING4
INPP5A
IQSEC1
IQSEC2
JARID1C
JHDM1D
KCNQ1
KDELC2
KIAA1890
LARP1
LDHC
LRP4
MBP
METTL2A
MGMT
MKRN1
MRPL33
MTNR1A
MYOM2
MYOM2
NGDN
NKX6-2
NMB
NMRAL1
NPM1
OR10J5
OR11H1
PCBP3
PDSS2
PGAM5
PIAS1
PIP5K1C
PRPF4B
PSMF1
RCN1
RIMBP2

chr19:934527-935866 (-16240)
chr5:154006880-154007581 (-169214)
chr4:174664266-174664967 (+23336)
chr16:4464076-4466962 (-823)
chr17:44025521-44026902 (-110)
chr16:1597101-1598101 (-302)
chrX:69198265-69200010 (-70905)
chr12:6642329-6643365 (-278)
chr10:134354410-134355581 (+153653)
chr3:12924512-12925212 (+59098)
chrX:53300308-53301009 (+66588)
chrX:53300308-53301009 (-29330)
chr7:139638566-139639267 (-115707)
chr11:1699992-3143916 (-843)
chr11:107873708-107875121 (-46)
chr8:2325222-2325923 (+928962)
chr5:154006880-154007581 (-107851)
chr11:18389628-18390682 (-279)
chr11:46914026-46915276 (-17999)
chr18:72820002-72820702 (+153410)
chr17:57854197-57855516 (-121)
chr10:131576120-131576820 (+421014)
chr7:139824758-139826571 (+106)
chr2:27847287-27848561 (-164)
chr4:187529470-187530572 (+183510)
chr8:2325222-2325923 (+345008)
chr8:2173367-2174068 (+193153)
chr14:23007937-23008937 (-301)
chr10:134354410-134355581 (+94531)
chr15:82977632-82978418 (+24781)
chr16:4464076-4466962 (-622)
chr5:170746602-170748260 (+28)
chr1:157772221-157773221 (-300)
chr22:14608025-14608726 (+221428)
chr21:45877482-45878832 (-216146)
chr6:107886688-107888248 (+4)
chr12:131806082-131806782 (+8923)
chr15:66132825-66134462 (+18)
chr19:3648693-3649393 (+2402)
chr6:3965767-3967073 (-148)
chr20:1046444-1047670 (-183)
chr11:32068466-32069853 (-107)
chr12:129691556-129692257 (-123492)
42

Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
Loss of methylation
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RP1L1
RPL32
SAP18
SCAND2
SCRG1
SFRS8
SH2D3C
SLC19A1
SLC37A3
SMOC2
SMOC2
SMOC2
SOX9
SPAG8
SPARCL1
SPATA20
SSTR5
STRA13
STX2
TAF10
TFF3
THBS2
THBS2
TMEM131
TOR2A
TRPV4
TSHZ1
TSNARE1
TTC15
UNQ9391
UQCC
VHL
YDJC
ZAP70
ZFP36L1
ZNF195
ZNF236
ZNF556
ZNF57
hCG_25025
AADAC
ADAM8
ADK

chr8:10486075-10486775 (+63602)
chr3:12924512-12925212 (-67913)
chr13:20611884-20613115 (-185)
chr15:82977632-82978418 (+2330)
chr4:174664266-174664967 (-107425)
chr12:130760787-130762407 (+9)
chr9:129573138-129574172 (+7078)
chr21:45877482-45878832 (-91378)
chr7:139638566-139639267 (+105863)
chr6:168513887-168514588 (-70642)
chr6:168679057-168679757 (+94527)
chr6:169166157-169167446 (+581922)
chr17:67624419-67625866 (-3613)
chr9:35801889-35803059 (-215)
chr4:88669330-88670330 (-151)
chr17:45968821-45969521 (-10257)
chr16:1082316-1084088 (+14332)
chr17:77545256-77546605 (+28131)
chr12:129691556-129692257 (+197857)
chr11:6589455-6590821 (-117)
chr21:42527874-42528575 (+80550)
chr6:168679057-168679757 (+716655)
chr6:169166157-169167446 (+229260)
chr2:97716500-97717903 (+261584)
chr9:129573138-129574172 (-36230)
chr12:108767404-108768105 (-12160)
chr18:71128507-71129207 (+77138)
chr8:142839591-142840292 (+642502)
chr2:3361652-3363020 (-117)
chr8:10486075-10486775 (+65934)
chr20:33463047-33464047 (-300)
chr3:10157518-10158973 (-73)
chr22:20316285-20317285 (-2445)
chr2:97716500-97717903 (+20739)
chr14:68332743-68333743 (-3705)
chr11:3356513-3357691 (-111)
chr18:72820002-72820702 (+155248)
chr19:2839720-2840421 (+21738)
chr19:2839720-2840421 (-11893)
chr14:100419019-100419719 (+51858)
chr3:153013750-153014750 (-301)
chr10:134948526-134949226 (-8514)
chr10:75605649-75606828 (+25268)
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Aβ Alters DNA Methylation of Cell-Fate Genes
BATF3
BEND7
BEND7
BEND7
C10orf93
C13orf16
C13orf28
C13orf3
C14orf180
C5orf45
C6orf70
C6orf89
C8orf42
COMT
DIP2A
DLGAP2
DLL1
EXOC2
FAM70B
GALNT2
GAS6
GLOD4
GNB1L
GPR123
GPR133
GPR133
GRIP1
GSTZ1
GTPBP6
GTPBP6
IGF2R
INPP5A
IRF4
KCNK9
KCNQ1
KIAA0649
KIF26A
KLF6
LOC339047
LYST
MAPK8IP3
METTL11A
MFSD10

chr1:210939083-210940750 (+33)
chr10:13556112-13556812 (+28520)
chr10:13553694-13554394 (+30938)
chr10:13554962-13555662 (+29670)
chr10:134726320-134728529 (-121371)
chr13:111717249-111718290 (+946754)
chr13:111865817-111866940 (-212291)
chr13:20849155-20849855 (-200795)
chr14:103966949-103968654 (-149299)
chr5:179209213-179209913 (+8883)
chr6:170295849-170296860 (+402709)
chr6:36960817-36962087 (-166)
chr8:1250830-1253745 (-766957)
chr22:18274383-18275428 (-34403)
chr21:46626893-46629188 (-75277)
chr8:1250830-1253745 (-184688)
chr6:170295849-170296860 (+145267)
chr6:464079-466338 (+172900)
chr13:113568450-113569450 (+82923)
chr1:228534950-228535650 (+265649)
chr13:113568450-113569450 (+22037)
chr17:659688-660388 (-27741)
chr22:18274383-18275428 (-52444)
chr10:134726320-134728529 (-6998)
chr12:129937778-129938478 (-66277)
chr12:130736641-130737341 (+732586)
chr12:65358820-65359820 (-300)
chr14:76856306-76857770 (-69)
chrY:243871-244571 (-73334)
chrX:243871-244571 (-73334)
chr6:160309320-160447571 (+68325)
chr10:134154101-134154801 (-46892)
chr6:464079-466338 (+128457)
chr8:141040229-141040929 (-256098)
chr11:1699992-3143916 (-843)
chr9:137290223-137291050 (-220832)
chr14:103966949-103968654 (+292989)
chr10:3490104-3490804 (+327001)
chr16:16321059-16321760 (-11802)
chr1:234113363-234114363 (-17020)
chr16:1730186-1730887 (+34315)
chr9:131290223-131290924 (-137682)
chr4:2926463-2927164 (-21247)
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Aβ Alters DNA Methylation of Cell-Fate Genes
MUC13
MYST4
MYT1
NID1
NME3
NOMO3
NOP14
NXN
OLFM1
PCMTD2
PCNT
PGBD5
PITRM1
POMT2
PPP2R3B
PPP2R3B
PPP2R4
PTPRN2
RAN
RER1
RPH3AL
RPH3AL
SEPHS1
SEPHS1
SEPHS1
SFRS8
SGCA
SKI
SLC22A1
SLC45A2
SMEK2
SMOC2
SOX1
SOX1
SPPL2B
SQSTM1
STK32C
TAF1A
THBS2
TMPRSS9
TNRC4
TRAPPC9
TTC32

chr3:126136070-126137070 (-300)
chr10:75605649-75606828 (-650146)
chr20:62280214-62280915 (+14294)
chr1:234113363-234114363 (+181241)
chr16:1730186-1730887 (+31174)
chr16:16321059-16321760 (+87520)
chr4:2926463-2927164 (+8102)
chr17:659688-660388 (+169722)
chr9:137290223-137291050 (+183727)
chr20:62280214-62280915 (-76927)
chr21:46626893-46629188 (+59577)
chr1:228534950-228535650 (+44690)
chr10:3490104-3490804 (-285451)
chr14:76856306-76857770 (-68)
chrX:243871-244571 (+23406)
chrY:243871-244571 (+23406)
chr9:131290223-131290924 (+377509)
chr7:157940649-157942073 (+131818)
chr12:129937778-129938478 (+15607)
chr1:2201880-2203741 (-110263)
chr17:56119-57232 (+145900)
chr17:252659-254674 (-51091)
chr10:13556112-13556812 (-126176)
chr10:13554962-13555662 (-125026)
chr10:13553694-13554394 (-123758)
chr12:130736641-130737341 (-24597)
chr17:45597589-45598589 (-301)
chr1:2201880-2203741 (+52817)
chr6:160309320-160447571 (-84407)
chr5:34020337-34021337 (-300)
chr2:55697771-55699053 (+205)
chr6:169051742-169052507 (+467245)
chr13:111865817-111866940 (+96465)
chr13:111717249-111718290 (-52144)
chr19:2298135-2300732 (+19805)
chr5:179209213-179209913 (+29115)
chr10:134154101-134154801 (-182984)
chr1:220829418-220830678 (-170)
chr6:169051742-169052507 (+343937)
chr19:2298135-2300732 (-41350)
chr1:149960410-149961111 (-4847)
chr8:141040229-141040929 (+497281)
chr2:19964485-19966025 (-30)
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Aβ Alters DNA Methylation of Cell-Fate Genes
VPS53
ZDHHC20
ZDHHC23
ZNF511

chr17:252659-254674 (+311179)
chr13:20849155-20849855 (+81918)
chr3:115148637-115150077 (-81)
chr10:134948526-134949226 (-23537)
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